$ONC

Lee Chan Henry sold $338K of ONC

Lee Chan Henry (SVP, General Counsel) sold 1,044 shares of BeOne Medicines Ltd. (ONC) at $323.69 ($0.34M total) on 2026-07-30.

Original reporting
SEC EDGAR · Lee Chan Henry
Published Aug 3, 2026, 9:18 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 3, 2026, 9:32 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ONC
Neutral
medium confidence
Mentioned
$ONC
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ONCNeutralLow
01

Why it matters

The newest fact is the specific sale: 1,044 shares sold at $323.6900 on 2026-07-30, totaling $337,932.36, with holdings after the transaction reported as 0 shares and no pre-arranged 10b5-1 plan.

02

Market read

Traders may note the insider fully exited after the sale, but there is no accompanying operational or financial catalyst in the text.

03

What to watch

Insider sales can be driven by diversification, tax planning, or pre-existing compensation schedules; without additional context, the signal-to-noise is low.

Relevance 4/10Novelty 4/10Timing: filed after-hours on 2026-08-03, covering a 2026-07-30 sale

Background

The article is a SEC Form 4 insider transaction disclosure for BeOne Medicines Ltd. (ONC).

Company-level read

Ticker impact

$ONCNeutralMedium confidence
Context

BeOne Medicines (ONC) disclosed an insider open-market sale by SVP General Counsel Lee Chan Henry of 1,044 shares at $323.69.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven and should fade unless followed by additional disclosures.

Evidence & confidence

The filing is primary-source and time-stamped, but it does not include new company performance, guidance, or corporate actions. Insider sales are common and the article provides no linkage to material events beyond the transaction details.

Market effects

No sector read-through is provided; this appears company-specific and transaction-specific.

None indicated.

None indicated.

Counterpoint

The absence of a 10b5-1 plan could be interpreted as less “mechanical,” but the filing still lacks any stated reason or linkage to negative fundamentals.

Key entities

  • BeOne Medicines Ltd.

    Subject of the Form 4 insider transaction disclosure (ticker ONC).

  • Lee Chan Henry

    SVP, General Counsel who sold 1,044 shares in an open-market sale.

Related articles

$ONCHigh

BeOne Medicines Ltd. (ONC): Results of Operations and Financial Condition

BeOne Medicines Ltd. (ONC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-q22026earningsr.htm EX-99.1 Document Exhibit 99.1 BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates • Total global revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year • BRUKINSA (zanubruti

$CRCLMed

Here Are Monday’s Best Wall Street Analyst Research Calls: Atmos Energy, Best Buy, Biogen, Capital One, Costco, Disney, Papa John’s International, Shopify, and More

The article lists Monday analyst calls and market moves. It highlights SK hynix’s Nasdaq debut, up about 12.8% to $168.01 after raising nearly $26.5B. It cites upgrades including BIIB to Buy at $235, COF to Buy at $229, and SHOP to Buy at $160, plus downgrades like BBY to Hold. Circle (CRCL) rose ~15% on OCC approval.

$ONCMed

BeOne Medicines (ONC): Citizens Sees an Inflection Point in Its Cancer Pipeline

Citizens kept a “Market Outperform” rating and $396 price target on BeOne Medicines (NASDAQ:ONC) after the company presented tumor clinical data at ASCO 2026. Citizens highlighted three pipeline programs: BGB-43395 (HR+/HER2- metastatic breast cancer), BG-C9074 (ovarian cancer maintenance), and BGB-B2033 (liver cancer). The target was based on discounted earnings and revenue multiples, with Citizens citing $4.85 billion cash and 88% gross margins.